Experience
Quality
Innovation

The Enhanced Mental Skills Test (EMST)

Setting a new standard in cognitive screening accuracy

51 Sawyer Road
Suite 340
Waltham, MA 02453
(781) 893-7600
Fax: (781) 647-3552

www.lifeplansinc.com


3 Consortium to Establish a Registry for Alzheimer’s Disease
The Enhanced Mental Skills Test (EMST) Setting a NEW STANDARD in Cognitive Screening Accuracy

The earliest stages of a dementing disorder - called Mild Cognitive Impairment (MCI) - can exist for an average of seven years before observable symptoms rob a person’s ability to perform essential tasks and function independently. Each year during this period, between 6% and 25% of individuals with MCI progress to dementia or Alzheimer’s disease.

To avoid the catastrophic costs of dementia, all stakeholders - including physicians, providers, insurers, caregivers and family members - must be able to recognize MCI as an early stage of cognitive decline. Until now, however, cognitive tests have failed to accurately identify those with MCI or very mild dementia - a fact that leaves clinicians in the dark and puts the affected individual’s independence and financial solvency at great risk.

The EMST captures and evaluates more comprehensive information than any other cognitive testing technology. Its unrivaled sensitivity and specificity in screening for the very earliest stages of cognitive decline make it the most scientifically validated of any test available. The EMST is easily administered, the results are available almost immediately. Once reviewed with a clinician, these results can lead to the most appropriate preventive treatment and further monitoring needed to delay progression. For individuals with MCI, this can mean an improved lifestyle and lower health care costs. For insurers, it can mean help in selecting new insurance applicants and managing potential claims costs.

Validated in Science

Research has demonstrated that the EMST accurately identifies those with MCI as well as all subsequent stages of dementia - with the highest reported accuracy levels in the relevant literature. The EMST shows an overall accuracy of 97%. It’s sensitivity for MCI is 98%, jumping to 99% for mild dementia and 100% for moderate and severe dementia. In addition to accurately identifying MCI, the EMST uses an algorithm to differentiate cognitive impairment from lapses in attention and concentration due to depression, cerebrovascular or subcortical disease, sleep deprivation and other disorders.

The EMST captures and evaluates more comprehensive information than any other cognitive testing technology. The EMST mimics the human memory process by focusing on the encoding and retrieval of information such as word lists. The EMST’s scoring is based on multiple factors that enhance its sensitivity and specificity in screening for the very earliest stages of cognitive decline. These include the number of words recalled during word trials, their word order, any changes in performance when recalling a word across working and episodic memory trials, and the person’s insight into his/her own memory ability.

Scoring “A” in Accuracy

The EMST captures and evaluates more comprehensive information than any other cognitive testing technology. Its unrivaled sensitivity and specificity in screening for the very earliest stages of cognitive decline make it the most scientifically validated of any test available. The EMST is easily administered, the results are available almost immediately. Once reviewed with a clinician, these results can lead to the most appropriate preventive treatment and further monitoring needed to delay progression. For individuals with MCI, this can mean an improved lifestyle and lower health care costs. For insurers, it can mean help in selecting new insurance applicants and managing potential claims costs.

Boost Classification Accuracy and Minimize Risk

As the first comprehensive test to clearly identify the earliest precursors to cognitive decline, the EMST delivers the information required to enable rapid preventative treatment and minimize health care costs. The end results?

More stable insurance premiums...

• more effective treatment plans...

• more independence for affected individuals...

• lower health care costs...

• greater financial protection for all concerned.

The EMST captures and evaluates more comprehensive information than any other cognitive testing technology.

The EMST evaluates many diverse factors to maximize accuracy when detecting cognitive dysfunction.

The EMST can cost as much as $174,000 - the average lifetime cost of care for Alzheimer’s. 6% - 25% of MCI patients progress to dementia or Alzheimer’s disease each year.

The downward trend becomes more obvious as impairment increases.

Bracing for Boomers

As today’s 77 million baby boomers quickly age into tomorrow’s senior citizens, a huge challenge faces families, employers, insurers and providers alike: how to assure that seniors can live independently as long as possible. This challenge arises from the fact that aging is the #1 risk factor for dementia, the leading disorder in preventing independent living. The financial repercussions associated with this challenge are staggering. The average lifetime cost of care for an individual with Alzheimer’s is currently $174,000 - and rising every year. Without effective screening to accurately identify the early stages of dementia, prevention becomes impossible and treatment less effective.

The EMST is easily administered, the results are available almost immediately. Once reviewed with a clinician, these results can lead to the most appropriate preventive treatment and further monitoring needed to delay progression. For individuals with MCI, this can mean an improved lifestyle and lower health care costs. For insurers, it can mean help in selecting new insurance applicants and managing potential claims costs.

Validated in Science

Research has demonstrated that the EMST accurately identifies those with MCI as well as all subsequent stages of dementia - with the highest reported accuracy levels in the relevant literature. The EMST shows an overall accuracy of 97%. It’s sensitivity for MCI is 98%, jumping to 99% for mild dementia and 100% for moderate and severe dementia. In addition to accurately identifying MCI, the EMST uses an algorithm to differentiate cognitive impairment from lapses in attention and concentration due to depression, cerebrovascular or subcortical disease, sleep deprivation and other disorders.

The EMST captures and evaluates more comprehensive information than any other cognitive testing technology.
The EMST captures and evaluates more comprehensive information than any other cognitive testing technology.

Introducing The Enhanced Mental Skills Test

With the Enhanced Mental Skills Test (EMST), LifePlans introduces the most advanced generation of cognitive screening. Easy to administer, the EMST can be implemented by trained staff in both controlled and community settings. The overall administration time is less than 15 minutes, minimizing the burden on all parties.

The EMST makes early detection results available almost immediately. Once reviewed with a clinician, these results can lead to the preventative treatment and frequent monitoring needed to delay progression. For individuals with MCI, this can mean an improved lifestyle and lower health care costs. For insurers, it can mean help in selecting new insurance applicants and managing potential claims costs.

Scoring 'A' in Accuracy

The EMST captures and evaluates more comprehensive information than any other cognitive testing technology. Its unrivaled accuracy takes the guesswork out of early detection and risk selection. In addition to accurately identifying MCI - as well as all subsequent stages of dementia - the EMST provides maximum insight into cognitive function through the following steps:

- Initial Instruction - to assess attention, comprehension and language
- Three Immediate Word List Repetitions - to assess executive function, attention, concentration and working memory
- Estimation of Performance - to assess executive function, judgment and reasoning
- Delayed Free Recall - to assess episodic and working memory
- Delayed Cued Recognition - to assess episodic memory

Validated in Science

The EMST is based on two scientifically accepted cognitive testing technologies: the first - the CERAD® Wordlist - is a subset of the CERAD battery widely acknowledged in the gold standard for dementia testing. The second is the original Mental Skills Test which was developed, tested and validated by Medical Care Corporation. This test is currently used in Alzheimer’s centers and medical facilities in the United States and Japan.

The EMST evaluates many diverse factors to maximize accuracy when detecting cognitive dysfunction.

The Predictive Power of the EMST

The EMST tests all key domains relevant to identifying MCI. These include executive function (abstract reasoning, judgment, insight and conceptual organization), working and episodic memory, comprehension, attention, concentration and language. In contrast, other screening tests typically focus only on these domains associated with later stages of cognitive decline.

While other cognitive tests rely on a single cut-off score to identify who may or may not have dementia, the EMST’s scoring is based on multiple factors that enhance its sensitivity and specificity in screening for the very earliest stages of cognitive decline. These include the number of words recalled during word trials, their word order, any changes in performance when recalling a word across working and episodic memory trials, and the person’s insight into his/her own memory ability.

Scoring factors include:

- Memory factors: 25%
- Visuospatial factors: 10%
- Attention and concentration: 25%
- Episodic memory: 10%
- Language and comprehension: 10%
- Executive function: 5%
- Cued recognition: 5%
- Delayed recall: 5%

Boost Classification Accuracy and Minimize Risk

As the first comprehensive test to clearly identify the earliest precursors to cognitive decline, the EMST delivers the information required to enable rapid preventive treatment and minimize health care costs. The end results:

- More stable insurance premiums
- More effective treatment plans
- More independence for affected individuals
- Greater financial protection for all concerned.
Experience Quality Innovation

The Enhanced Mental Skills Test (EMST)
Setting a new standard in cognitive screening accuracy

51 Sawyer Road
Suite 340
Waltham, MA 02453
(781) 893-7600
Fax: (781) 647-3552
www.lifeplansinc.com


3 Consortium to Establish a Registry for Alzheimer’s Disease